Despite the impact of the pandemic on cancer care, Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to ...

and earlier this year launched a phase 3 study in previously untreated patients – DESTINY-Breast09 – which is comparing Enhertu with or without Roche's Perjeta (pertuzumab) to Perjeta ...